What is HC Wainwright’s Forecast for JANX Q1 Earnings?

Janux Therapeutics, Inc. (NASDAQ:JANX) – HC Wainwright issued their Q1 2027 EPS estimates for shares of Janux Therapeutics in a note issued to investors on Monday, May 11th. HC Wainwright analyst S. Ramakanth expects that the company will earn ($0.56) per share for the quarter. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Janux Therapeutics’ Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.63) EPS, Q4 2027 earnings at ($0.66) EPS and FY2030 earnings at $1.06 EPS.

JANX has been the topic of a number of other research reports. Weiss Ratings upgraded shares of Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 22nd. UBS Group lowered shares of Janux Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the company from $57.00 to $15.00 in a research note on Wednesday, April 15th. Truist Financial upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Monday, May 4th. JonesTrading decreased their price target on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, April 28th. Finally, Cantor Fitzgerald decreased their price target on shares of Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $45.85.

Janux Therapeutics Stock Performance

Shares of JANX stock opened at $14.23 on Tuesday. The firm’s 50-day moving average is $14.37 and its 200-day moving average is $17.27. The stock has a market cap of $867.75 million, a price-to-earnings ratio of -7.73 and a beta of 2.58. Janux Therapeutics has a 52-week low of $12.12 and a 52-week high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.13. The firm had revenue of $3.73 million during the quarter, compared to the consensus estimate of $4.36 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in JANX. AQR Capital Management LLC grew its position in shares of Janux Therapeutics by 71.7% during the 1st quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock worth $262,000 after purchasing an additional 4,059 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Janux Therapeutics by 18.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,403 shares of the company’s stock worth $583,000 after purchasing an additional 3,393 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Janux Therapeutics by 12.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 186,394 shares of the company’s stock worth $5,033,000 after purchasing an additional 20,657 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Janux Therapeutics by 82.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 247,424 shares of the company’s stock worth $5,715,000 after purchasing an additional 112,116 shares in the last quarter. Finally, Legal & General Group Plc grew its position in shares of Janux Therapeutics by 12.0% during the 2nd quarter. Legal & General Group Plc now owns 47,353 shares of the company’s stock worth $1,094,000 after purchasing an additional 5,055 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.